HETEROCYCLIC COMPOUND AND USE THEREOF

The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of...

Full description

Saved in:
Bibliographic Details
Main Authors TOKUNAGA, Norihito, NAKAMURA, Shinji, TAKAMI, Kazuaki, TAKASHIMA, Sachie, KAMEI, Taku, AIDA, Jumpei, IWANAGA, Kouichi, YAMAMOTO, Satoshi, NAKAMURA, Minoru, DAINI, Masaki, SETO, Masaki, KAMATA, Makoto, WADA, Yasufumi, WAKABAYASHI, Takeshi, MIKAMI, Satoshi, MURAKAMI, Masataka, KAKEI, Hiroyuki, TAWARAISHI, Taisuke, MATSUMOTO, Shigemitsu, OGURO, Yuya, ITO, Mitsuhiro, MORIMOTO, Shinji
Format Patent
LanguageEnglish
French
German
Published 17.02.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I):wherein each symbol is as described in the description, or a salt thereof.
Bibliography:Application Number: EP20190721865